Meridian Bioscience (VIVO) Tops Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Meridian Bioscience (VIVO) Tops Q4 EPS by 3c

Meridian Bioscience (VIVO) Receives FDA Emergency Use Authorization for Revogene SARS-CoV-2 Molecular Assay

November 10, 2021 8:55 AM EST

Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that their Revogene® SARS-CoV-2 assay was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). Meridian expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021.

The Revogene® SARS-CoV-2 assay is a molecular... More